MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

(2016) E. A. Punnoose et al.   MOLECULAR CANCER THERAPEUTICS

Mitochondria—Judges and Executioners of Cell Death Sentences

(2016) Patrick D. Bhola et al.   MOLECULAR CELL

Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia

(2016) Kevin H. Lin et al.   Scientific Reports

Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members

(2015) Joseph T. Opferman   FEBS Journal

Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients

(2015) S Jilg et al.   LEUKEMIA

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

(2015) Y. Xiao et al.   MOLECULAR CANCER THERAPEUTICS

New dimension in therapeutic targeting of BCL-2 family proteins

(2015) Samaher Besbes et al.   Oncotarget

Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in Cells

(2014) Glenna Wink Foight et al.   ACS Chemical Biology

Regulating cell death at, on, and in membranes

(2014) Xiaoke Chi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

(2014) G. L. Kelly et al.   GENES & DEVELOPMENT

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies

(2014) J M Bogenberger et al.   LEUKEMIA

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL

(2014) Michael F. T. Koehler et al.   ACS Medicinal Chemistry Letters

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

(2014) Zhi-Fu Tao et al.   ACS Medicinal Chemistry Letters

Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-XL

(2013) Brad E. Sleebs et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure-guided design of a selective BCL-XL inhibitor

(2013) Guillaume Lessene et al.   Nature Chemical Biology

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

(2013) R. Pan et al.   Cancer Discovery

Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML

(2012) Thanh-Trang Vo et al.   CELL

Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells

(2012) Hideko Akagi et al.   Gastric Cancer

Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors

(2012) G. J. Gores et al.   GENES & DEVELOPMENT

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

(2012) S. P. Glaser et al.   GENES & DEVELOPMENT

Rational Design of Proteolytically Stable, Cell-Permeable Peptide-Based Selective Mcl-1 Inhibitors

(2012) Avinash Muppidi et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Identification of a Novel Mcl-1 Protein Binding Motif

(2011) William J. Placzek et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex

(2011) M Konopleva et al.   LEUKEMIA

Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP9X and Mcl-1

(2011) C. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

(2010) D. Yecies et al.   BLOOD

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

(2010) Scott Ackler et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The BCL-2 Family Reunion

(2010) Jerry E. Chipuk et al.   MOLECULAR CELL

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer

(2010) Michelle L Stewart et al.   Nature Chemical Biology

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

(2010) H Zhang et al.   ONCOGENE

Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell

(2008) San-Hua Wei et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

(2008) A. R. Shoemaker et al.   CLINICAL CANCER RESEARCH

Bcl-2 family proteins and cancer

(2008) K W Yip et al.   ONCOGENE